Bio-Techne Corporation (BVMF:T1CH34)

Brazil flag Brazil · Delayed Price · Currency is BRL
7.75
-0.28 (-3.49%)
At close: May 11, 2026
Market Cap36.41B -19.4%
Revenue (ttm)6.32B +0.2%
Net Income571.23M -16.8%
EPS3.62 -15.4%
Shares Outn/a
PE Ratio63.74
Forward PE23.35
Dividend0.04 (0.49%)
Ex-Dividend DateFeb 12, 2026
Volume151
Average Volume51
Open8.03
Previous Close8.03
Day's Range7.75 - 8.03
52-Week Range7.53 - 12.57
Beta1.41
RSI36.13
Earnings DateAug 5, 2026

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 3,100
Stock Exchange Brazil Stock Exchange
Ticker Symbol T1CH34

Financial Performance

In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Financial numbers in USD Financial Statements

News

Bio-Techne price target lowered to $66 from $75 at Deutsche Bank

Deutsche Bank analyst Justin Bowers lowered the firm’s price target on Bio-Techne (TECH) to $66 from $75 and keeps a Buy rating on the shares.

4 days ago - TheFly

Bio-Techne price target lowered to $49 from $70 at Baird

Baird lowered the firm’s price target on Bio-Techne (TECH) to $49 from $70 and keeps a Neutral rating on the shares. The firm updated its model following Q3 organic growth…

5 days ago - TheFly

Bio-Techne price target lowered to $50 from $65 at Stifel

Stifel lowered the firm’s price target on Bio-Techne (TECH) to $50 from $65 and keeps a Hold rating on the shares.

5 days ago - TheFly

Bio-Techne price target lowered to $50 from $54 at Evercore ISI

Evercore ISI analyst Daniel Markowitz lowered the firm’s price target on Bio-Techne (TECH) to $50 from $54 and keeps an In Line rating on the shares.

5 days ago - TheFly

Bio-Techne price target lowered to $70 from $80 at Citi

Citi lowered the firm’s price target on Bio-Techne (TECH) to $70 from $80 and keeps a Buy rating on the shares. The firm reduced the company’s estimates post the fiscal…

5 days ago - TheFly

Bio-Techne price target lowered to $62 from $76 at Wells Fargo

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Bio-Techne (TECH) to $62 from $76 and keeps an Overweight rating on the shares. The firm notes the shares…

5 days ago - TheFly

Bio-Techne reports Q3 adjusted EPS 53c, consensus 53c

Reports Q3 revenue $311.42M, consensus $316.06M. “The Bio-Techne (TECH) team delivered solid execution amid a mixed end-market environment,” said Kim Kelderman, President and Chief Executive Officer o...

5 days ago - TheFly

Bio-Techne Earnings Call Transcript: Q3 2026

Q3 saw a 2% organic revenue decline due to biotech softness and order timing, but large pharma and China remained strong. Adjusted operating margin improved sequentially, and underlying growth was positive when excluding cell therapy and OEM timing. Biotech recovery is expected in FY2027.

6 days ago - Transcripts

Bio-Techne misses revenue estimates as US academic funding cuts dent demand

Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. ​academic funding weighed on demand for its drug-development ‌products.

6 days ago - Reuters

Bio-Techne Releases Third Quarter Fiscal 2026 Results

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026. Third Quarter FY2026 Highlights Reporte...

6 days ago - PRNewsWire

Bio-Techne Declares Dividend

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 20...

6 days ago - PRNewsWire

Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference

MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities...

8 days ago - PRNewsWire

Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The new bran...

26 days ago - PRNewsWire

Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results

MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to...

4 weeks ago - PRNewsWire

Bio-Techne price target lowered to $54 from $68 at Evercore ISI

Evercore ISI lowered the firm’s price target on Bio-Techne (TECH) to $54 from $68 and keeps an In Line rating on the shares as part of the firm’s medical technology…

5 weeks ago - TheFly

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows.  SPYRE™ Amplification Kits leverage sequential and enhanced l...

6 weeks ago - PRNewsWire

Bio-Techne Transcript: Leerink Global Healthcare Conference 2026

Pharma and China are driving growth, while biotech and academic markets are rebounding as funding returns. Fiscal 2026 guidance is cautious but optimistic, with margin expansion expected through differentiated products and operational improvements.

2 months ago - Transcripts

Bio-Techne Transcript: TD Cowen 46th Annual Health Care Conference

Celebrating its 50th anniversary, the company is leveraging a diversified portfolio and four growth verticals to drive future growth. Strong performance in large pharma and improving biotech funding support confidence in mid-single digit growth by fiscal 2026, while margin expansion and strategic M&A remain key priorities.

2 months ago - Transcripts

Bio-Techne to Present at Upcoming Investor Conferences

MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference...

2 months ago - PRNewsWire

Bio-Techne’s Ella platform achieves CE-IVD marking, available for sale in E.U.

Bio-Techne (TECH) Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union, E.U.. This achievement brings Ella’...

3 months ago - TheFly

Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories

Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with m...

3 months ago - PRNewsWire

Bio-Techne Announces Changes to its Leadership Team

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Div...

3 months ago - PRNewsWire

Bio-Techne price target raised to $68 from $62 at Evercore ISI

Evercore ISI analyst Daniel Markowitz raised the firm’s price target on Bio-Techne (TECH) to $68 from $62 and keeps an In Line rating on the shares. The company’s Q4 guidance…

3 months ago - TheFly

Bio-Techne price target raised to $65 from $60 at Stifel

Stifel raised the firm’s price target on Bio-Techne (TECH) to $65 from $60 and keeps a Hold rating on the shares. The company delivered a beat in fiscal Q2, but…

3 months ago - TheFly

Bio-Techne price target raised to $80 from $70 at TD Cowen

TD Cowen raised the firm’s price target on Bio-Techne (TECH) to $80 from $70 and keeps a Buy rating on the shares. The firm updated its model following its Q2…

3 months ago - TheFly